Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Restless Legs Syndrome Market: By Medication Type, Tricyclic Antidepressants, Others), By End User, By Geography
Restless Legs Syndrome Market size was valued at US$ X billion in 2022 and is expected to reach US$ X billion by 2028, at a significant CAGR of 3.7% from 2023-2029. Restless legs syndrome (RLS), otherwise called Willis-Ekbom infection, is a condition that causes awkward sensations, regularly in the legs. These sensations have been portrayed as tingly, slithering, disturbing sensations, and make the staggering urge move the influenced appendage. RLS side effects commonly happen when the individual is sitting, resting, or dozing, and regularly occur around evening time. The developments caused by RLS are called periodic limb movements of sleep (PLMS). On account of these developments, RLS can cause serious sleep issues. The presently accessible medications in restless legs syndrome can just conveyed to target particular patients for symptomatic alleviation as it were. Also, a portion of the unfriendly impacts, for example, sensory system issue that incorporate migraine, dazedness, sedation, sickness, fart and dry mouth. Mental disarranges, including diminished charisma and wretchedness. Digestion and healthful issue, including expanded hunger and weight pick up; ear issue, maze issue and other normal issue, for example, peevishness, exhaustion, and fringe edema are connected with the utilization of these medications. In this way the treatment methodology for the fretful legs disorder is as yet not extremely famous and not embraced by the medicinal services specialist co-op on a bigger part. The improvement of new medications that have higher productivity and the insignificant reaction would be exceedingly refreshing in the restless legs syndrome market.
Study Period
2024-2030Base Year
2023CAGR
3.7%Largest Market
EuropeFastest Growing Market
North-America
The higher predominance of restless legs syndrome is noted in ladies than in men. RLS can influence individuals everything being equal yet is for the most part seen in moderately aged and elderly individuals. The most well-known manifestations of RLS incorporate awkward tingling and torment in the legs that may cause a disturbance in the rest design and at last influence a patients personal satisfaction. In spite of its expanding commonness, the exact reason for RLS isnt yet known. Nevertheless, with broad examinations being led in the field, the RLS market is relied upon to pick up energy sooner rather than later. Starting at now, specialists quality the expanding occurrence of the malady to hereditary elements and insecurities in the dopaminergic adjust.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market CAGR |
3.7% |
By Medication Type |
|
By End User |
|
By Region |
|
Download Free Sample Report
The key segments covered in the restless leg’s syndrome market are technology, components, application, and end-users.
The Restless legs syndrome market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The Restless legs syndrome market key player is Biogen, Inc (U.S), Pfizer, Inc. (U.S), Johnson & Johnson Services, Inc. (U.S), Eli Lilly & Company (U.S), Merck & Co., Inc. (U.S), AstraZeneca (UK), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Shire Plc. (Ireland), GlaxoSmithKline (UK)
1.Executive Summary |
2.Global Restless Legs Syndrome Market Introduction |
2.1.Global Restless Legs Syndrome Market - Taxonomy |
2.2.Global Restless Legs Syndrome Market - Definitions |
2.2.1.Medication Type |
2.2.2.End User |
2.2.3.Region |
3.Global Restless Legs Syndrome Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Restless Legs Syndrome Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Restless Legs Syndrome Market By Medication Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. Antihistamines |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Anti-nausea drugs |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Antipsychotic drugs |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Selective Serotonin Reuptake Inhibitors (SSRIs) |
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Tricyclic Antidepressants |
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Others |
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6.Global Restless Legs Syndrome Market By End User, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. Hospital Pharmacies |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Retail Pharmacies |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Online Pharmacies |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7.Global Restless Legs Syndrome Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8.North America Restless Legs Syndrome Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. Medication Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.Antihistamines |
8.1.2.Anti-nausea drugs |
8.1.3.Antipsychotic drugs |
8.1.4.Selective Serotonin Reuptake Inhibitors (SSRIs) |
8.1.5.Tricyclic Antidepressants |
8.1.6.Others |
8.2. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Hospital Pharmacies |
8.2.2.Retail Pharmacies |
8.2.3.Online Pharmacies |
8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9.Europe Restless Legs Syndrome Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. Medication Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Antihistamines |
9.1.2.Anti-nausea drugs |
9.1.3.Antipsychotic drugs |
9.1.4.Selective Serotonin Reuptake Inhibitors (SSRIs) |
9.1.5.Tricyclic Antidepressants |
9.1.6.Others |
9.2. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Hospital Pharmacies |
9.2.2.Retail Pharmacies |
9.2.3.Online Pharmacies |
9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
9.3.6.Rest of EU |
10.Asia Pacific (APAC) Restless Legs Syndrome Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Medication Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Antihistamines |
10.1.2.Anti-nausea drugs |
10.1.3.Antipsychotic drugs |
10.1.4.Selective Serotonin Reuptake Inhibitors (SSRIs) |
10.1.5.Tricyclic Antidepressants |
10.1.6.Others |
10.2. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Hospital Pharmacies |
10.2.2.Retail Pharmacies |
10.2.3.Online Pharmacies |
10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11.Middle East and Africa (MEA) Restless Legs Syndrome Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Medication Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Antihistamines |
11.1.2.Anti-nausea drugs |
11.1.3.Antipsychotic drugs |
11.1.4.Selective Serotonin Reuptake Inhibitors (SSRIs) |
11.1.5.Tricyclic Antidepressants |
11.1.6.Others |
11.2. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Hospital Pharmacies |
11.2.2.Retail Pharmacies |
11.2.3.Online Pharmacies |
11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12.Latin America Restless Legs Syndrome Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Medication Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Antihistamines |
12.1.2.Anti-nausea drugs |
12.1.3.Antipsychotic drugs |
12.1.4.Selective Serotonin Reuptake Inhibitors (SSRIs) |
12.1.5.Tricyclic Antidepressants |
12.1.6.Others |
12.2. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Hospital Pharmacies |
12.2.2.Retail Pharmacies |
12.2.3.Online Pharmacies |
12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.Biogen, Inc (U.S). |
13.2.2.Pfizer, Inc. (U.s) |
13.2.3.Johnson & Johnson Services, Inc. (U.S) |
13.2.4.Eli Lilly & Company (U.S) |
13.2.5.Merck & Co., Inc. (U.S) |
13.2.6.AstraZeneca (UK) |
13.2.7.Novartis AG (Switzerland) |
13.2.8.Teva Pharmaceutical Industries Ltd.(Israel) |
13.2.9.Shire Plc. (Ireland) |
13.2.10.GlaxoSmithKline (UK) |
14. Research Methodology |
15. Appendix and Abbreviations |
Key Market Players